Notably, they observed a synergistic effect on cell growth inhibition with the combination of ACSL4 inhibitor rosiglitazone and ERα inhibitor tamoxifen both in ER+ and triple-negative breast cancer cells, indicating an ER independence function of tamoxifen, which has been reported to increase ROS levels and induce premature senescence and cell cycle arrest in breast cancer cells [289, 291]. This evidence concerns the gene ACSL4 and breast cancer.